Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bray

Showing results (1041-1050 of 1,079) with videos related to

Pageof 108
Sort By:
Bioorganic & Medicinal Chemistry|October 20, 2009
Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indolesGavin D Heffernan, Richard D Coghlan, Eric S Manas, et al.
Transplantation|October 25, 2000
Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejectionA R Tambur, R A Bray, S K Takemoto, et al.
Journal of the American Dietetic Association|August 18, 1999
The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research GroupL P Svetkey, F M Sacks, E Obarzanek, et al.
Journal of Medicinal Chemistry|February 6, 2010
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitorsAn T Vu, Stephen T Cohn, Puwen Zhang, et al.
Journal of the American Geriatrics Society|September 28, 2016
Effects of Longitudinal Glucose Exposure on Cognitive and Physical Function: Results from the Action for Health in Diabetes Movement and Memory StudyKristen M Beavers, Iris Leng, Stephen R Rapp, et al.
The New England Journal of Medicine|March 25, 2011
Pioglitazone for diabetes prevention in impaired glucose toleranceRalph A DeFronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Clinical Pharmacology and Therapeutics|September 11, 2009
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacyR Krishna, B Gumbiner, C Stevens, et al.
The New England Journal of Medicine|February 28, 2009
Comparison of weight-loss diets with different compositions of fat, protein, and carbohydratesFrank M Sacks, George A Bray, Vincent J Carey, et al.
Journal of Medicinal Chemistry|September 16, 2011
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152)David J O'Neill, Adedayo Adedoyin, Jenifer A Bray, et al.
The Journal of Clinical Endocrinology and Metabolism|January 21, 2015
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW studyDevjit Tripathy, Jeff E Cobb, Walter Gall, et al.
Pageof 108

Showing results (1041-1050 of 1,079) with videos related to

Sort By:
Pageof 108
Bioorganic & Medicinal Chemistry|October 20, 2009
Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indolesGavin D Heffernan, Richard D Coghlan, Eric S Manas, et al.
Transplantation|October 25, 2000
Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejectionA R Tambur, R A Bray, S K Takemoto, et al.
Journal of the American Dietetic Association|August 18, 1999
The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research GroupL P Svetkey, F M Sacks, E Obarzanek, et al.
Journal of Medicinal Chemistry|February 6, 2010
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitorsAn T Vu, Stephen T Cohn, Puwen Zhang, et al.
Journal of the American Geriatrics Society|September 28, 2016
Effects of Longitudinal Glucose Exposure on Cognitive and Physical Function: Results from the Action for Health in Diabetes Movement and Memory StudyKristen M Beavers, Iris Leng, Stephen R Rapp, et al.
The New England Journal of Medicine|March 25, 2011
Pioglitazone for diabetes prevention in impaired glucose toleranceRalph A DeFronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Clinical Pharmacology and Therapeutics|September 11, 2009
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacyR Krishna, B Gumbiner, C Stevens, et al.
The New England Journal of Medicine|February 28, 2009
Comparison of weight-loss diets with different compositions of fat, protein, and carbohydratesFrank M Sacks, George A Bray, Vincent J Carey, et al.
Journal of Medicinal Chemistry|September 16, 2011
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152)David J O'Neill, Adedayo Adedoyin, Jenifer A Bray, et al.
The Journal of Clinical Endocrinology and Metabolism|January 21, 2015
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW studyDevjit Tripathy, Jeff E Cobb, Walter Gall, et al.
Pageof 108